- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1613-7671
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer ; volume:134 ; number:1-2 ; day:28 ; month:1 ; year:2022 ; pages:63-72 ; date:1.2022
Wiener klinische Wochenschrift ; 134, Heft 1-2 (28.1.2022), 63-72, 1.2022
- Urheber
-
Bartsch, Rupert
Gampenrieder, Simon Peter
Rinnerthaler, Gabriel
Petru, Edgar
Egle, Daniel
Petzer, Andreas
Balic, Marija
Pluschnig, Ursula
Sliwa, Thamer
Singer, Christian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00508-021-01987-9
- URN
-
urn:nbn:de:101:1-2022051220411123924185
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bartsch, Rupert
- Gampenrieder, Simon Peter
- Rinnerthaler, Gabriel
- Petru, Edgar
- Egle, Daniel
- Petzer, Andreas
- Balic, Marija
- Pluschnig, Ursula
- Sliwa, Thamer
- Singer, Christian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
HER2-targeted therapy influences CTC status in metastatic breast cancer
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
HER2-targeted therapy influences CTC status in metastatic breast cancer
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer